Teva Pharmaceutical Industries (TEVA) Free Cash Flow (2017 - 2026)

Teva Pharmaceutical Industries has disclosed Free Cash Flow across 10 years of filings, most recently posting -$208.0 million for Q1 2026.

• Quarterly Free Cash Flow rose 10.34% year-over-year to -$208.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 53.2% YoY) and the FY2025 annual result came in at $1.1 billion, up 53.27% from the prior year.
• Free Cash Flow retreated to -$208.0 million in Q1 2026, from $1.0 billion in the prior quarter.
• Over five years, Free Cash Flow peaked at $1.1 billion in Q4 2023 and troughed at -$284.0 million in Q1 2023.
• A 5-year average of $210.2 million and a median of $131.0 million in 2025 frame the typical range for Free Cash Flow.
• Biggest YoY gain for Free Cash Flow was 5225.0% in 2023; the steepest drop was 134.2% in 2023.
• Tracing TEVA's Free Cash Flow over 5 years: stood at $831.0 million in 2022, then advanced by 28.16% to $1.1 billion in 2023, then slumped by 58.12% to $446.0 million in 2024, then surged by 127.8% to $1.0 billion in 2025, then plunged by 120.47% to -$208.0 million in 2026.
• Business Quant data shows TEVA's Free Cash Flow at -$208.0 million in Q1 2026, $1.0 billion in Q4 2025, and $233.0 million in Q3 2025.